OTLK logo

OTLKOutlook Therapeutics Inc

$0.8083
$0.0053
(0.65%)
Today
Updated: 03:58 PM EDT
Reported EarningsMay 15
Mkt Cap$98.33M
Vol9.63M
News
all
press releases
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal
A decision on the resubmitted application is expected within 60 days of the FDA’s receipt of it, the company said.
Stocktwits
News Placeholder
More News
News Placeholder
OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record
Outlook Therapeutics wins appeal following formal dispute resolution process for LYTENAVA.
Stocktwits
News Placeholder
Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday
Redwire, T1 Energy, and Outlook Therapeutics shares soared due to broad sectoral optimism, strong institutional backing, and positive company developments, respectively.
Stocktwits
News Placeholder
Traders Rush into AI, Biotech, and Emerging Tech
Momentum traders are aggressively rotating into AI infrastructure, biotech catalysts, blockchain exposure, and emerging technology plays as speculative appetite continues heating up across small-cap and high-growth sectors. $KBLB, $OTLK, $PHGE, $UZX, $QTEK $ARTL, $VCIG, $YMAT, $NCRA
24-7 Market News
News Placeholder
Outlook Therapeutics Stock Climbs 38% After Winning FDA Appeal For NAMD Therapy
(RTTNews) - Shares of Outlook Therapeutics, Inc. (OTLK) are climbing about 38 percent in Tuesday morning trading after the company announced that the U.S. FDA has granted its appeal following completion of the Formal Dispute Resolution process for ONS-5010/LYTENAVA, its investiga...
Nasdaq News: Markets
News Placeholder
OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone – What’s Behind This Massive Rally?
The U.S. Food and Drug Administration granted Outlook Therapeutics its appeal following a formal dispute resolution process related to its eye disease drug Lytenava.
Stocktwits
News Placeholder
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -33.33% and -97.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug
Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.read more...
Benzinga
News Placeholder
Why Is OTLK Stock Falling Today?
Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.
Stocktwits
News Placeholder
Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -26.95% and -131.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>